Subjects -> MEDICAL SCIENCES (Total: 8695 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (220 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (339 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (235 journals)
    - DENTISTRY (294 journals)
    - DERMATOLOGY AND VENEREOLOGY (164 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (124 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (42 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (189 journals)
    - GERONTOLOGY AND GERIATRICS (138 journals)
    - HEMATOLOGY (158 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (178 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (99 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2420 journals)
    - NURSES AND NURSING (371 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (386 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (140 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (170 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (275 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (159 journals)
    - PSYCHIATRY AND NEUROLOGY (835 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (192 journals)
    - RESPIRATORY DISEASES (105 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (405 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (155 journals)

LABORATORY AND EXPERIMENTAL MEDICINE (99 journals)

Showing 1 - 98 of 98 Journals sorted alphabetically
AAPS PharmSciTech     Hybrid Journal   (Followers: 9)
Actualites Pharmaceutiques     Full-text available via subscription   (Followers: 7)
Adipocyte     Open Access   (Followers: 1)
African Journal of Laboratory Medicine     Open Access   (Followers: 2)
American Journal of Experimental and Clinical Research     Open Access   (Followers: 4)
American Journal of Medical and Biological Research     Open Access   (Followers: 11)
Animal Models and Experimental Medicine     Open Access  
Annals of Clinical Chemistry and Laboratory Medicine     Open Access   (Followers: 5)
Applied In Vitro Toxicology     Hybrid Journal   (Followers: 2)
Archives of Clinical and Experimental Medicine     Open Access  
Archives of Medical Research     Hybrid Journal   (Followers: 3)
Archives of Pathology & Laboratory Medicine     Full-text available via subscription   (Followers: 32)
Archives of Preventive Medicine     Open Access   (Followers: 3)
Biomedical Engineering     Hybrid Journal   (Followers: 3)
Bulletin of Experimental Biology and Medicine     Hybrid Journal  
Clinica Chimica Acta     Hybrid Journal   (Followers: 30)
Clinical & Experimental Metastasis     Hybrid Journal  
Clinical and Experimental Medical Journal     Full-text available via subscription   (Followers: 1)
Clinical and Experimental Medicine     Hybrid Journal   (Followers: 4)
Clinical Trials     Hybrid Journal   (Followers: 21)
Clinical Trials in Degenerative Diseases     Open Access  
Clinical Trials in Orthopedic Disorders     Open Access   (Followers: 1)
Current Medicine Research and Practice     Full-text available via subscription  
Current Research in Drug Discovery     Open Access   (Followers: 1)
Drug Design, Development and Therapy     Open Access   (Followers: 4)
Ecography     Hybrid Journal   (Followers: 27)
European Journal of Hospital Pharmacy : Science and Practice (EJHP)     Hybrid Journal   (Followers: 9)
European Journal of Medical Research     Open Access   (Followers: 1)
European Journal of Nanomedicine     Hybrid Journal   (Followers: 1)
Experimental & Molecular Medicine     Open Access   (Followers: 1)
Experimental Aging Research: An International Journal Devoted to the Scientific Study of the Aging Process     Hybrid Journal   (Followers: 3)
Experimental and Therapeutic Medicine     Full-text available via subscription   (Followers: 1)
Experimental Biology and Medicine     Hybrid Journal   (Followers: 3)
Expert Opinion on Drug Delivery     Hybrid Journal   (Followers: 20)
Frontiers in Laboratory Medicine     Open Access  
Frontiers in Medical Technology     Open Access   (Followers: 1)
IN VIVO     Full-text available via subscription   (Followers: 5)
International Archives of Biomedical and Clinical Research     Open Access  
International Journal of Experimental Pathology     Hybrid Journal   (Followers: 1)
International Journal of Health Research and Innovation     Open Access   (Followers: 1)
International Journal of Research in Medical Sciences     Open Access   (Followers: 7)
International Journal of Statistics in Medical Research     Hybrid Journal   (Followers: 5)
Journal of Cell Science & Therapy     Open Access   (Followers: 1)
Journal of Applied Biomaterials & Functional Materials     Hybrid Journal   (Followers: 1)
Journal of Biomedical and Clinical Research     Open Access  
Journal of Clinical Laboratory Analysis     Open Access   (Followers: 14)
Journal of Clinical Medicine and Research     Open Access  
Journal of Clinical Medicine Research     Open Access   (Followers: 4)
Journal of Clinical Trials     Open Access   (Followers: 6)
Journal of Current and Advance Medical Research     Open Access   (Followers: 1)
Journal of Current Medical Research and Practice     Open Access  
Journal of Current Research in Scientific Medicine     Open Access  
Journal of Drug Delivery and Therapeutics JDDT     Open Access   (Followers: 1)
Journal of Enzyme Inhibition and Medicinal Chemistry     Open Access   (Followers: 4)
Journal of Experimental & Clinical Medicine     Full-text available via subscription   (Followers: 1)
Journal of Experimental & Clinical Cancer Research     Open Access   (Followers: 2)
Journal of Experimental and Clinical Medicine     Open Access  
Journal of Experimental Medicine     Full-text available via subscription   (Followers: 46)
Journal of Experimental Pharmacology     Open Access   (Followers: 2)
Journal of Histotechnology     Hybrid Journal   (Followers: 2)
Journal of International Medical Research     Open Access   (Followers: 3)
Journal of Investigative Medicine High Impact Case Reports     Open Access  
Journal of Medicine and Biomedical Research     Open Access   (Followers: 1)
Journal of Muhammadiyah Medical Laboratory Technologist     Open Access  
Journal of Operating Department Practitioners     Full-text available via subscription   (Followers: 2)
Journal of the American Society of Cytopathology     Hybrid Journal   (Followers: 6)
Journal of Trace Elements in Medicine and Biology     Hybrid Journal   (Followers: 1)
Lab on a Chip     Full-text available via subscription   (Followers: 42)
Laboratory Investigation     Hybrid Journal   (Followers: 3)
Medical Devices & Sensors     Hybrid Journal  
Medical Image Analysis     Hybrid Journal   (Followers: 15)
Medical Instrumentation     Open Access  
Medical Laboratory Observer     Full-text available via subscription  
Medical Laboratory Technology Journal     Open Access  
Medicinal Chemistry Research     Hybrid Journal   (Followers: 12)
Medtech Insight     Full-text available via subscription   (Followers: 4)
Nanomedicine: Nanotechnology, Biology and Medicine     Hybrid Journal   (Followers: 7)
New Zealand Journal of Medical Laboratory Science     Full-text available via subscription   (Followers: 1)
Oriental Pharmacy and Experimental Medicine     Partially Free   (Followers: 3)
Pathology and Laboratory Medicine International     Open Access   (Followers: 7)
Physical Biology     Hybrid Journal   (Followers: 4)
Practical Laboratory Medicine     Open Access   (Followers: 2)
Proceedings of the Institution of Mechanical Engineers Part H: Journal of Engineering in Medicine     Hybrid Journal   (Followers: 3)
Prosthetics and Orthotics International     Hybrid Journal   (Followers: 10)
Pulse     Full-text available via subscription  
Qualitative Research in Medicine & Healthcare     Open Access  
Recent Advances in Biology and Medicine     Open Access  
Regulatory Toxicology and Pharmacology     Hybrid Journal   (Followers: 43)
Reproduction     Full-text available via subscription   (Followers: 7)
Revista Peruana de Medicina Experimental y Salud P├║blica     Open Access  
Revista Romana de Medicina de Laborator     Open Access  
RSC Medicinal Chemistry     Full-text available via subscription   (Followers: 6)
SA Pharmacist's Assistant     Open Access  
Savannah Journal of Medical Research and Practice     Full-text available via subscription  
SLAS Technology     Hybrid Journal   (Followers: 2)
Statistics in Medicine     Hybrid Journal   (Followers: 190)
Trends in Molecular Medicine     Full-text available via subscription   (Followers: 14)
Turkish Journal of Clinics and Laboratory     Open Access   (Followers: 1)
Similar Journals
Journal Cover
European Journal of Hospital Pharmacy : Science and Practice (EJHP)
Journal Prestige (SJR): 0.213
Number of Followers: 9  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 2047-9956 - ISSN (Online) 2047-9964
Published by BMJ Publishing Group Homepage  [68 journals]
  • Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug
           selection by means of the System of Objectified Judgement Analysis
    • Authors: Janknegt, R; van den Beuken, M, Schiere, S, Überall, M, Knaggs, R, Hanley, J, Thronaes, M.
      Abstract: Drug selection of rapid acting fentanyl formulations in the treatment of breakthrough pain in patients with cancer is performed by the System of Objectified Judgement Analysis method. All seven available formulations were included in the analysis. The following selection criteria were used: number of available strengths, variability in the rate of absorption, interactions, clinical efficacy, side effects, ease of administration and documentation. No direct double-blind comparative studies between two or more formulations were identified and the clinical documentation of all formulations is limited. The most distinguishing criterion was ease of use. This led to slightly higher scores for Abstral, Instanyl and PecFent than for the other formulations. The pros and cons of each formulation should be discussed with the patient, and the most suitable formulation selected for each individual patient.
      Keywords: Open access
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2016-001127
      Issue No: Vol. 25, No. 3 (2018)
       
  • Change blindness
    • Authors: Wiffen P.
      Pages: 117 - 117
      Keywords: Anaesthesia
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2018-001587
      Issue No: Vol. 25, No. 3 (2018)
       
  • QTc prolongation during erythromycin used as prokinetic agent in ICU
           patients
    • Authors: Fiets, R; Bos, J, Donders, A, Bruns, M, Lamfers, E, Schouten, J, Kramers, C.
      Pages: 118 - 122
      Abstract: BackgroundHigh-dose erythromycin used as antibiotic prolongs QTc interval. Low-dose erythromycin is frequently used as a prokinetic agent, especially in patients in the intensive care unit (ICU). It is unknown whether low-dose erythromycin affects cardiac repolarisation and puts patients at risk for torsades de pointes.MethodsIn this prospective study, we included ICU patients treated with erythromycin as prokinetic in a dose of 200 mg twice a day. An ECG was performed before, 15 min and 24 hours after the start of erythromycin. Cardiac repolarisation was assessed by rate-corrected analysis of the QT interval (QTc) on the ECG by two independent investigators. Starting or stopping other possibly QTc prolonging drugs during the study period was an exclusion criterion. Wilcoxon signed-rank test and Friedman's test were used for statistical analysis to assess prolongation of QTc. Primary outcome was defined by the prolongation of QTc after 15 min and 24 hours.Results51 patients were eligible for this study. In these patients, QTc increased significantly from 430 ms at baseline to 439 ms (p=0.03) after 15 min and 444 ms (p=0.01) after 24 hours. After 15 min and 24 hours, the upper limit of 95% CI for prolongation of QTc was well above 10 ms. No QTc-related arrhythmias were seen.ConclusionsDuring treatment with erythromycin in a dose of 200 mg twice a day. QTc prolonged mildly but significantly. Sequential ECG registration should be performed when low-dose erythromycin is prescribed, especially in the presence of other risk factor for QTc prolongation.
      Keywords: EAHP Statement 5: Patient Safety and Quality Assurance
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2016-001077
      Issue No: Vol. 25, No. 3 (2018)
       
  • Individualised antimicrobial dosing in critically ill patients undergoing
           continuous renal replacement therapy: focus on total drug clearance
    • Authors: Ruiz, J; Favieres, C, Broch, M. J, Villarreal, E, Gordon, M, Quinza, A, Castellanos Ortega, A, Ramirez, P.
      Pages: 123 - 126
      Abstract: BackgroundContinuous renal replacement therapy (CRRT) is common practice in critical care patients with acute renal failure.ObjectivesTo evaluate the adequacy of antimicrobial doses calculated based on the total drug clearance and dose recommended by different guides in critically ill patients undergoing CRRT.MethodsRetrospective observational study. Patients admitted to a critical care unit during May 2014 to May 2016 and subjected to CRRT were included. The recommended dose was established as the product of the usual dose of the drug by total drug clearance.Results177 antimicrobial agents, used in 64 patients were analysed; 45 (25.4%) antimicrobials were given in an insufficient dose (
      Keywords: EAHP Statement 4: Clinical Pharmacy Services
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2016-001114
      Issue No: Vol. 25, No. 3 (2018)
       
  • Predictors of primary non-adherence to concomitant chronic treatment in
           HIV-infected patients with antiretroviral therapy
    • Authors: Borrego, Y; Gomez-Fernandez, E, Jimenez, R, Cantudo, R, Almeida-Gonzalez, C. V, Morillo, R.
      Pages: 127 - 131
      Abstract: ObjectivesTo identify the independent risk factors of primary non-adherence to chronic concomitant treatment in HIV-positive patients, and to measure primary and secondary non-adherence rates to chronic treatments, and secondary non-adherence to antiretroviral therapy and the prevalence of concomitant chronic diseases.MethodsWe conducted a retrospective study that included HIV-infected patients with antiretroviral treatmentwho attended the pharmaceutical care office between January and December 2012. The dependent variable was primary non-adherence to concomitant prescription drugs for chronic diseases. To know the predictors of concomitant primary non-adherence, we performed a univariate analysis and a multivariate binary logistic regression model to identify the independent predictors of primary non-adherence to co-medication.ResultsOut of 598 patients analysed, 333 patients had a new co-medication prescribed during the studied period. The number of comorbidities per patient was 2.3 and the patients were treated with an average of 3.4 drugs. The rates of primary and secondary non-adherence to co-medication were 8.4% and 44.4%, respectively. The co-occurrence of primary and secondary non-adherence was 24.9%. The number of comorbidities (p=0.001) and co-medications (p=0.001) was significantly higher in patients who had primary non-adherence to co-medication. Furthermore, there was a statistically significant relationship between primary non-adherence and patients treated with psychotropic drugs (p=0.03). The multivariate analysis showed the independent predictor of primary non-adherence to co-medication was the number of co-medications (p
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2016-001000
      Issue No: Vol. 25, No. 3 (2018)
       
  • Anaemia predictors in patients with chronic hepatitis C treated with
           ribavirin and direct-acting antiviral agents
    • Authors: Molina-Cuadrado, E; Mateo-Carrrasco, H, Collado, A, Casado Martin, M.
      Pages: 132 - 137
      Abstract: ObjectivesAnaemia is the most common side effect associated with ribavirin (RBV). This study intended to assess its incidence and determine its predictive factors in patients with hepatitis C virus on RBV plus direct-acting antiviral agents (DAAs).MethodsA retrospective study of patients receiving RBV+DAA was conducted. Serum haemoglobin (Hb) was determined at baseline and monitored 4 weekly. Anaemia was defined as a single occurrence of Hb
      Keywords: EAHP Statement 4: Clinical Pharmacy Services, EAHP Statement 5: Patient Safety and Quality Assurance
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2017-001277
      Issue No: Vol. 25, No. 3 (2018)
       
  • Impact of fampridine on quality of life: clinical benefit in real-world
           practice
    • Authors: Marzal-Alfaro, M. B; Martin Barbero, M. L, Garcia Dominguez, J, Romero-Delgado, F, Martinez Gines, M. L, Herranz, A, Sanjurjo-Saez, M.
      Pages: 138 - 143
      Abstract: ObjectivesTo assess the effectiveness and tolerability of fampridine in patients with multiple sclerosis (MS) in real clinical practice and to analyse adherence to treatment and general satisfaction of patients in terms of quality of life (QOL).MethodsPatients who started treatment with fampridine from May 2014 to October 2014 were included. Primary and secondary outcomes were Timed 25-Foot Walk (T25FW) and MS Walking Scale-12 (MSWS-12) respectively, measured at baseline and 2 weeks, 3 and 6 months. Adherence was measured by the Morisky–Green questionnaire, patient satisfaction with a visual analogue scale (VAS) and QOL with improvement in mobility, self-care, daily activities, pain/discomfort or anxiety/depression.Results30 patients (46.7% women) of mean age 39 years, mean MS duration 13.7 years, mean Expanded Disability Status Scale score 5.8, 57% with relapsing-remitting MS were included. 22 patients (73%) continued to take treatment throughout the study period. Two weeks after treatment initiation all measures improved significantly from baseline (T25FW: –7.5 s, p
      Keywords: EAHP Statement 4: Clinical Pharmacy Services
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2016-001129
      Issue No: Vol. 25, No. 3 (2018)
       
  • Furosemide ethanol-free oral solutions for paediatric use: formulation,
           HPLC method and stability study
    • Authors: Zahalka, L; Klovrzova, S, Matysova, L, Sklubalova, Z, Solich, P.
      Pages: 144 - 149
      Abstract: BackgroundOral liquid solutions of the diuretic active ingredient furosemide (FUR) marketed across Europe do not comply with recent requirements for paediatric preparation owing to their ethanol content and, moreover, in some countries only tablet or injection dosage forms of furosemide are available.ObjectivesTo formulate extemporaneous paediatric ethanol-free solutions of FUR (2 mg/mL) with suitable solubility in the aqueous vehicle and an acceptable taste and to evaluate their stability under two different storage conditions during a 9-month study period.MethodsOur work presents two developed formulations of FUR ethanol-free paediatric oral solutions 2 mg/mL for easy extemporaneous compounding in a pharmacy. FUR solubility avoiding the use of ethanol was achieved using sodium hydroxide (formulation F1) or disodium hydrogen phosphate dodecahydrate (formulation F2). The preparations were stored at 25°C±3°C or at 40°C±0.5°C and protected from light. For FUR and preservative, methylparaben (MP), a stability assay was conducted by a high-performance liquid chromatography validated method and determination of pH stability.ResultsThe remaining FUR concentration was>90% of the initial concentration after 270 days in both formulations at both storage conditions, 25°C and 40°C. The concentration of MP decreased significantly in the formulation F2 stored at 40°C.ConclusionsBoth formulations were stable when stored at room temperature for up to 9 months; formulation F1 was stable even at 40°C. MP used as an antimicrobial agent fully satisfied the recommended criteria for preservative efficacy in oral preparations according to the European Pharmacopoeia 9.0 (5.1.3).
      Keywords: Editor''s choice, EAHP Statement 3: Production and Compounding
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2017-001264
      Issue No: Vol. 25, No. 3 (2018)
       
  • Compatibility of proton pump inhibitors in a preservative-free suspending
           vehicle
    • Authors: Polonini, H. C; Silva, S. L, Loures, S, Almy, R, Balland, A, Brandao, M. A. F, Ferreira, A. O.
      Pages: 150 - 156
      Abstract: ObjectivesTo evaluate the microbiological and physicochemical compatibility of commonly used proton pump inhibitors (PPIs) esomeprazole, lansoprazole, omeprazole and pantoprazole compounded at a single concentration using SyrSpend SF Alka and stored at refrigerated temperatures (omeprazole was also stored at room temperature because it has the most widespread use).MethodsCompatibility was assessed by measuring the per cent recovery at varying time points throughout a 90-day period. Quantification of the APIs was performed by a validated high performance liquid chromatography (HPLC-UV) method. This same assay was also used to determine the dosage content uniformity of the suspensions. Microbiological stability (‘test in use’) was assessed during 60 days and total aerobic microbial count (TAMC), total combined yeasts and moulds count (TYMC), detection of Escherichia coli and pH determination were performed. Antimicrobial effectiveness testing was determined following European Pharmacopoeia guidelines.ResultsBeyond-use dates of maximum 60 days for omeprazole (5 mg/mL), pantoprazole (3 mg/mL) and esomeprazole (3 mg/mL) were established. All suspensions that met the physicochemical criteria for stability also met the content uniformity criteria. The suspensions showed no antimicrobial efficiency against bacteria, yeasts and moulds as SyrSpend SF Alka is an unpreserved vehicle, but the ‘test in use’ showed that the suspensions can remain microbiologically stable for up to 60 days.ConclusionsSyrSpend SF Alka can be used to compound palatable (taste-masking properties) preservative-free oral suspensions with almost all commonly used PPIs.
      Keywords: EAHP Statement 3: Production and Compounding
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2016-001034
      Issue No: Vol. 25, No. 3 (2018)
       
  • Evaluation of the physicochemical and biological stability of
           reconstituted and diluted SB2 (infliximab)
    • Authors: Kim, J; Chung, J, Park, S, Jung, S, Kang, D.
      Pages: 157 - 164
      Abstract: ObjectivesTo evaluate the critical quality attributes that might affect the stability of an infliximab biosimilar (SB2, Flixabi) when reconstituted or diluted and stored under refrigeration and at room temperature.MethodsWe largely adhered to the UK's National Health Service guidance requirements for the design of a robust stability study and for robust testing methods. Protocol components included evaluation of visual appearance, chemical stability, physical stability, pH, particle sizes and biological activity. The stability of reconstituted SB2 was assessed for 60 days at 5°C and for 7 days at 25°C. Stability of diluted SB2 at concentrations that ranged from 240 mg/250 mL (3 mg/kg; 80 kg patient) to 400 mg/250 mL (5 mg/kg; 80 kg patient) was assessed for 7 days at both temperatures. Dilutions were made in polyethylene bags containing 0.9% NaCl. Forced degradation studies were conducted with SB2 and its reference product (USA-sourced and European Union-sourced Remicade). Stress conditions of heat or light occurred before product reconstitution.ResultsIn a laboratory environment under aseptic conditions, stability acceptance criteria with regard to physicochemical and biological properties were met for all reconstituted and diluted SB2 samples for all time periods and temperatures assessed. After either heat or light stress, similar stability and biological activity were noted for SB2 and both reference products.ConclusionsWhen prepared under aseptic conditions in accordance with the product's Summary of Product Characteristics, exposed for prolonged periods at 5°C and 25°C and assessed with the described methods, SB2 appears to remain a stable monoclonal antibody maintaining its expected biological function.
      Keywords: Open access, EAHP Statement 5: Patient Safety and Quality Assurance
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2016-001085
      Issue No: Vol. 25, No. 3 (2018)
       
  • Chinese centralised intravenous admixture service (CIVAS), an emerging
           pharmaceutical industry: survey of the recent advances of CIVAS in China
    • Authors: Mi, W; Li, L, Zhang, Y, Yang, P, Miao, P, Liu, X.
      Pages: 165 - 168
      Abstract: PurposeTo present the results of a survey involving 97 centralised intravenous admixture service (CIVAS) centres in China to review the recent advances of Chinese CIVAS.Methods103 CIVAS centres in first- or second-class Chinese hospital settings were surveyed by email questionnaire.ResultsNinety-seven centres responded(response rate 94%). With regard to scale and output issues, large CIVAS centres with a daily output of more than 10 000 bags accounted for 10% while the per workbench and per square metre output varied dramatically among different centres. For personnel structure, 80% of CIVAS centres chose the combination model of pharmacy and nursing. For the CIVAS operation model, more than 80% of centres adopted the drug centralised compounding model.ConclusionCIVAS centres are playing an important role in Chinese hospital pharmacy and have developed into an emerging pharmaceutical industry. The development of Chinese CIVAS centres is very variable. With regard to the personnel structure, the pharmacy–nursing combination model is recommended, while the operation model should be selected according to specific hospitals. Universal guidelines for CIVAS operation and personnel training are urgently needed.
      Keywords: EAHP Statement 3: Production and Compounding
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2016-001154
      Issue No: Vol. 25, No. 3 (2018)
       
  • European Directorate for the Quality of Medicines: automatic drugs
           dispensing report
    • Authors: Kohl S.
      Pages: 169 - 172
      Keywords: Anaesthesia, EAHP Statement 6: Education and Research
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2018-001585
      Issue No: Vol. 25, No. 3 (2018)
       
  • EAHP releases medicines shortage survey to improve patient outcomes
    • Authors: Kohl S.
      Pages: 173 - 174
      Keywords: Anaesthesia, EAHP Statement 6: Education and Research
      PubDate: 2018-04-25T03:20:22-07:00
      DOI: 10.1136/ejhpharm-2018-001586
      Issue No: Vol. 25, No. 3 (2018)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.237.66.86
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-